Bioinvent International AB

BioInvent International AB (publ) is a clinical-stage company that discovers and develops immuno-modulatory antibodies for cancer therapy. It operates in Sweden, Europe, the United States, and internationally. Its drug candidates include BI-1808, BI-1206, BI-1910, BI-1607, and BT-001, which are in various clinical trial phases for solid tumors, T-cell lymphoma, and non-Hodgkin's lymphoma. The company has collaborations with Transgene, MSD, CASI Pharmaceuticals, AstraZeneca, and XOMA. Incorporated in 1996, BioInvent is based in Lund, Sweden.